The following ventures have been selected by the
INCATE Selection Committee
Tackling resistant infections with virulence inhibition.
Invitris developed the worldwide first platform technology to synthesize arbitrary phages within a single system, thus enabling full scalability of therapeutic phage isolation, modification, production, and application.
Myxobiotics is a start-up company discovering and developing novel antibiotics from natural products first isolated and characterized from myxobacteria.
At smartbax we develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Developing novel anti-virulence agents for multi drug resistant TB and difficult to treat infectious diseases
An innovative and selective treatment against stomach diseases caused by Helicobacter pylori
Rostra Therapeutics is committed to bringing novel medicines to patients and clinicians delivering the power to restore health and save lives globally
Pedanius Therapeutics is developing RNAi therapeutics using two complimentary, bacterial delivery platform technologies silencing genes critical to bacterial growth and survival, thus introducing a versatile, novel modality into the battle against antimicrobial resistance
AMResolute is an early stage drug discovery and development company combating antibiotic-resistant bacterial infections through innovation, applying customised narrow spectrum antibiotics with a novel mode of action
Olgram is a preclinical stage biotechnology company, creating new drugs to fight bacterial persisters (bacteria in a dormant state responsible for infectious relapses), by using an original approach on new chemical entities discovered in the sea
Fagoterapia LAB is the biotech producing and commercializing tailor-made drugs based on good viruses (phage) to cure antibiotic resistant infections. To develop its products FL will leverage on a technology platform based on a proprietary AI-algorithm and on a phage biobank
Oxford Silk Phage Technologies
OSPT is developing a new material integrating bacteriophage viruses, to produce medical implants reducing surgical site infections and the need for antibiotics
Developing novel Darobactin analogues
S. aureus α-hemolysin Inhibitors
The Helmholtz Centre for infection Research together with the Lead Discovery Center develop small molecule-based inhibitors of alpha-hemolysin to treat lung infections caused by Staphylococcus aureus
MyxoBiomedical develops a resistance-breaking macrolide antibiotic based on the myxobacterial natural product scaffold chlorotonil for the treatment of infections caused by MRSA/VRE
Kinzbio is discovering phages that have been overlooked by standard discovery pipelines and have unique and previously unknown biological properties, leveraging their use for infection prevention
At CC Bio, we harness the power of synthetic biology to engineer and edit the microbiome with precision antimicrobials. Our goal is to eliminate microbiome-based disease in a potent, specific and prophylactic fashion, harmonising the relationship between eukaryotic and microbial cells.
The following ventures were selected
at INCATE pitch events
LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation vaccines for the prevention of life-threatening diseases.
an ultra-fast, low cost, high-throughput Antimicrobial Susceptibility Test suitable for all bacterial infections